Authors: Jessica Klusek, Jinkuk Hong, Audra Sterling, Elizabeth Berry-Kravis, and Marsha Mailick
The study team thanks the participants for their time and effort in participating in the study and Dr. Elizabeth Berry-Kravis and the Molecular Diagnostic Laboratory at Rush University for their assistance in molecular testing.
Summary
Doctoral student Walker McKinney, Dr. Matt Mosconi, and colleagues investigated how aging as a premutation carrier may affect sensorimotor (exactly as it sounds, both sensory and motor) brain systems. Premutation carriers of the FMR1 gene are at risk of developing Fragile X-associated tremor/ataxia syndrome (FXTAS), and although several studies have documented sensorimotor issues in aging premutation carriers before the onset of clinical symptoms of FXTAS, the brain processes associated with sensorimotor issues and their potential to serve as early indicators of FXTAS have not been determined.
This study included 16 FMR1 premutation carriers and 18 control participants. Participants’ brain activity was measured with functional magnetic resonance imaging (fMRI) while they performed a test of sensorimotor control. Participants were instructed to grip a handle that measured their force level while they received visual feedback about how hard they were pressing. Participants viewed a white force bar that moved upward with increased force and downward with decreased force and a red static target bar (A) that turned green to begin each trial. Participants were instructed to press (C) so that the white force bar stayed as steady as possible at the level of the green target bar (B). Participants completed this sensorimotor task while the fMRI machine recorded small changes in blood flow in the parts of the brain that were active during the task.
Sensorimotor test stimuli and custom fiber-optic transducer (C; Neuroimaging Solutions, Gainesville, FL). Participants pressed when the red bar (A) turned green (B) in order to move the white bar up to the target green bar. They were instructed to maintain their force level at the level of the green bar as steadily as possible.
Researchers found that the functional connectivity of the cerebellum (a brain area that controls movement accuracy and timing) and the extrastriate cortex (a brain area involved in processing visual information) is reduced in aging FMR1 premutation carriers. This suggests that communication between visual processing regions in the brain and the cerebellum, a brain region critical for monitoring and adjusting movements so that they are accurate, is disrupted during aging in FMR1 premutation carriers and may be an early indicator of FXTAS.
Why This Matters
Researchers have struggled to find biomarkers to indicate who might develop FXTAS and who is showing early signs of neurodegeneration before the emergence of clear clinical concerns. These findings meant that functional connectivity between the cerebellum and extrastriate cortex could serve as a biomarker for FXTAS. This potential biomarker could help researchers and clinicians better predict which premutation carriers may develop FXTAS before they experience the tell-tale symptoms (e.g., kinetic tremor, gait issues).
Next Steps
Researchers will need to follow these participants over time to see if these functional connectivity differences are in fact a biomarker or an early indicator for FXTAS. More research using sensorimotor tasks and connectivity measurements is needed to further understand this potential biomarker.
Funding: This work was supported by the Once Upon a Time Foundation and the National Institutes of Health (U54 HD090216).
more research results
Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives
Most individuals with FXS cannot state themselves that they are anxious and self-report is needed in current standardized assessments. The information analyzed in this study will result in the development of a measure where observable and quantifiable data on anxiety in those with FXS can become an outcome measure to be used in future research/trials.
Neuropsychological Changes in FMR1 Premutation Carriers and Onset of FXTAS
This is the first time that Fragile X premutation carriers have been tracked in a longitudinal study. This study provides evidence for early markers of FXTAS that may be helpful in eventually identifying the best candidates for early, preventive intervention.
The International Fragile X Premutation Registry: Building a Resource for Research and Clinical Trial Readiness
The first published publication from the International Fragile X Premutation Registry Advisory Committee. This International Fragile X Premutation Registry is an important first step and can serve as a useful tool for clinicians and researchers in the field.
The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations
Thanks to The European Fragile X Network, FMR1 now stands for fragile X messenger ribonucleoprotein 1, removing the reference to “mental retardation” which has long been outdated in common vernacular.
Optimal Time Lags From Causal Prediction Model Help Stratify and Forecast Nervous System Pathology
Being able to identify and diagnose possible nervous system disorders by detecting gait problems 15 to 20 years before their clinical diagnosis could help advance treatment development and quality of life.
Prodromal Markers of Upper Limb Deficits in FMR1 Premutation Carriers and Quantitative Outcome Measures for Future Clinical Trials in FXTAS
This system could potentially predict FXTAS onset in premutation carriers who are not showing signs of FXTAS on a neurological exam.